首页> 外文OA文献 >PND2 Cost Offsets and Gains in Health Effects in the Treatment of Relapsing–Remitting Multiple Sclerosis with Laquinimod: An Analysis Based on the Allegro Trial

【2h】

PND2 Cost Offsets and Gains in Health Effects in the Treatment of Relapsing–Remitting Multiple Sclerosis with Laquinimod: An Analysis Based on the Allegro Trial

机译：用拉喹莫德治疗复发缓解型多发性硬化症的PND2成本抵消和健康影响中的收益：基于Allegro试验的分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ekman M.; White R.E.; Buck P.E.; Justo N.; Lindgren P;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis [J] . Terranova Nadia, Hicking Christine, Dangond Fernando, Clinical pharmacokinetics . 2019,第3期

机译：克拉迪斯施用第二年延期治疗的影响：复发式多发性硬化症患者绝对淋巴细胞计数和复发率的临床试验仿真分析
2. COST-UTILITY ANALYSIS OF DIMETHYL FUMARATE AS A FIRST SWITCH TREATMENT FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM [J] . Fahham L., Murta L., Teich V, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第3期

机译：富马酸二甲酯作为缓解巴西公共卫生系统多发性硬化的首次开关的成本效用分析
3. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments [J] . Shekoufeh Nikfar, Abbas Kebriaeezadeh, Rassoul Dinarvand, Daru Journal of pharmaceutical sciences. . 2013,第1期

机译：针对复发缓解和继发进行性多发性硬化症的不同干扰素β产品的成本效益：基于长期临床数据和可转换治疗的决策分析
4. GPU Accelerated Analysis of Treg-Teff Cross Regulation in Relapsing-Remitting Multiple Sclerosis [C] . Marco Beccuti, Paolo Cazzaniga, Marzio Pennisi, International Conference on Parallel and Distributed Computing . 2019

机译：GPU在复发延迟多发性硬化中的Treg-Teff交叉调节的分析
5. Cost-Effectiveness of Oral Agents in Relapsing-Remitting Multiple Sclerosis Compared to Interferon-Based Therapy in Saudi Arabia [D] . Alskaabi, May. 2017

机译：沙特阿拉伯口服药物在复发缓解型多发性硬化症中的成本效果与基于干扰素的疗法相比
6. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis [O] . Nadia Terranova, Christine Hicking, Fernando Dangond, -1

机译：克拉屈滨治疗第二年推迟治疗的效果：复发-释放性多发性硬化症患者绝对淋巴细胞计数和复发率的临床试验模拟分析
7. PND34 Long-Term Effects on Costs and Quality Adjusted Life Years of Patients With Relapsing-Remitting Multiple Sclerosis Treated With Laquinimod: Results Based on the Allegro and Bravo Trials [O] . Lang A., Tuomari A., Kobelt G., 2012

机译：PND34对拉喹莫德治疗的复发缓解型多发性硬化症患者的费用和质量调整生命年的长期影响：基于Allegro和Bravo试验的结果

PND2 Cost Offsets and Gains in Health Effects in the Treatment of Relapsing–Remitting Multiple Sclerosis with Laquinimod: An Analysis Based on the Allegro Trial

著录项

引文网络

相似文献

相关主题

期刊订阅